Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report 8 additional genes with suggestive evidence of association, including the DNA repair genes PARP2 and MSH6 Finally, we observed an excess of rare truncation variants in 5 genes, including the DNA repair genes MSH6, BRCA1, and BRCA2 This adds to the growing body of evidence that DNA repair pathway defects may influence susceptibility to aggressive prostate cancer.
|
27486019 |
2016 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that mismatch repair gene polymorphism could be a risk factor for prostate cancer and p53 Pro/Pro genotype carriers could influence MSH3 and MSH6 polymorphisms.
|
18355840 |
2008 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy.
|
23559371 |
2013 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, the present study investigated the gene expression profile of six major MMR genes, viz. hMLH1, hMSH2, hPMS1, hPMS2, hMSH3, and hMSH6, and polymorphism in hMLH1 and hMSH2 in Pca in Indian population.
|
21348638 |
2011 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
|
27803051 |
2017 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although the vast majority of AR mutations appeared capable of increased activation in response to ART-27, an AR mutation identified in prostate cancer (AR P340L) and AIS (AR E2K) show reduced transcriptional responses to ART-27, whereas their response to the p160 class of coactivators was not diminished.
|
15919721 |
2005 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.
|
25255306 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this article is to provide a review of principles of genetic testing in prostate cancer and highlight the significance of clinical genetic testing of BRCA1/2 and other genes (CHEK2, HOXB13, PALB2), including Lynch syndrome genes (MLH1, MSH2, MSH6, and PMS2) in men with metastatic prostate cancer.
|
30681994 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of germline mutations in DNA damage repair genes ( BRCA1, BRCA2, CHEK2, ATM and PALB2) and in DNA mismatch repair genes ( MLH1, MSH2, MSH6 and PMS2) can drive the development of prostate cancer.
|
30730411 |
2019 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MMR-related genes (hMLH1, hPMS1, hPMS2, hMSH2, hMSH3, hMSH6) showed mRNA transcripts in all prostate cancer cell lines.
|
11444857 |
2001 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MSH6 overexpression could be a marker of aggressiveness in PrCa.
|
31209634 |
2019 |